>유럽 제약용 분리기 시장, 유형별(무균 분리기, 격리 분리기, 생물학적 분리기, 샘플링 및 계량 분리기, 활성 제약 성분(API) 제조 분리기, 방사성 약제 분리기, 생산 분리기, 기타), 시스템 유형(폐쇄형 시스템, 개방형 시스템), 압력(양압, 음압), 구성(바닥형, 모듈형, 모바일형, 콤팩트형, 테이블탑형, 휴대용 , 기타), 응용 분야(멸균 테스트, 제조, 샘플링/계량/유통, 의료 기기 제조), 최종 사용자(병원, 진단 실험실, 학술 및 연구 기관, 제약 및 생명 공학 회사, 계약 연구 기관, 기타), 유통 채널(직접 입찰, 소매 판매, 제3자 유통업체) 산업 동향 및 2029년까지의 예측.
유럽 제약용 분리기 시장 분석 및 통찰력
제약용 분리기는 제약 산업에서 오염 없는 장벽 시스템으로 사용됩니다. 미생물 검사, 세포 치료 처리, 첨단 제약(ATMP) 제조, 멸균 주사 제품의 계량, 포장 및 유통은 제약용 분리기의 몇 가지 응용 분야일 뿐입니다. 제약용 분리기의 사용은 개발도상국과 선진국에서 제약 시장의 지속적인 성장과 혁신적인 치료법을 생산하기 위한 R&D 지출 증가로 인해 촉진되었습니다. 첨단 의료용 절연체와 제약 산업의 요구 사항으로 인해 주요 제조업체는 의료용 절연체 산업을 성장시켰습니다. 유해 화합물의 사용 증가, 비준수 비용 증가, 연구실 증가는 예측 기간 동안 제약용 분리기 시장을 주도하는 중요한 요인입니다.
그러나 대부분의 전문가들은 규제 기관이 더 이상 제약용 절연체 개발과 같은 획기적인 발전을 방해할 수 없다는 데 동의하지 않습니다.
Data Bridge Market Research는 유럽 제약 아이솔레이터 시장이 2029년까지 1,857.44백만 달러에 도달할 것으로 예상되며, 예측 기간 동안 CAGR은 13.8%라고 분석했습니다. 유형은 이 지역에서 제약 아이솔레이터에 대한 수요가 빠르게 증가함에 따라 시장에서 가장 큰 유형 세그먼트를 차지합니다. 이 시장 보고서는 또한 가격 분석, 특허 분석 및 기술 발전에 대한 심층적인 내용을 다룹니다.
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2022년부터 2029년까지 |
|
기준 연도 |
2021 |
|
역사적 연도 |
2020 (2019-2014까지 사용자 정의 가능) |
|
양적 단위 |
매출은 백만 달러, 볼륨은 단위, 가격은 달러로 표시됨 |
|
다루는 세그먼트 |
By Type (Aseptic Isolators, Containment Isolators, Bio Isolators, Sampling And Weighing Isolators, Active Pharmaceutical Ingredient (API) Manufacturing Isolators, Radiopharmaceutical Isolators, Production Isolators, Others), System Type (Closed System, Open System), Pressure (Positive Pressure, Negative Pressure), Configuration (Floor Standing, Modular, Mobile, Compact, Table Top, Portable, Others), Application (Sterility Testing, Manufacturing, Sampling/ Weighing/ Distribution, Medical Device Manufacturing), End User (Hospitals, Diagnostic Laboratories, Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Others), Distribution Channel (Direct Tender, Retail Sales, Third Party Distributors). |
|
Countries Covered |
Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland and the rest of Europe, |
|
Market Players Covered |
Getinge, SKAN AG, Hosokawa micron ltd, Gelman Singapore, Azbil Corporation, Germfree Laboratories, Inc., M. Braun Inertgas-Systeme Gmbh, Nuaire, Iteco S.R.L., Comecer S.P.A., Hecht Technologie Gmbh, Steriline S.R.L., Envair Limited, Tema Sinergie S.P.A, Schematic Engineering Industries, Chiyoda Corporation, Chamunda Pharma Machinery Pvt. Ltd, Bioquell (Ecolab Solution), Jacomex, Fedegari Autoclavi S.p.A., LAF Technologies, ISO Tech Design, Cytiva, Esco Pharma among others. |
Europe Pharmaceutical Isolator Market Definition
The isolation concept protects the process from the Operator and or the operator from the process, while protecting the environment. The key to containment, is minimal exposure. By controlling the exposure range below the hazard level set for the compound, the Operator and the environment are properly protected. Hence, the product is protected and therefore a key regulatory issue is addressed. A pharmaceutical isolator is a sealed bacterial enclosure used in the pharmaceutical surrounding for aseptic filling and toxic process. It is made of a perfectly sterile main isolator where the products are handled, stored or packaged using shoulder-high gloves placed on one of the walls. The pharmaceutical isolator enables the control and containment of pharmaceutical processes. The conditions required for working of a pharmaceutical isolator are sterile environment and free of viable microorganisms. A pharmaceutical isolator ensures that production area and aseptic environment are placed in separate positions. A pharmaceutical industry isolator is cost effective and efficient, in comparison to cleanrooms for the pharmaceutical industry in an aseptic environment. It creates a controlled atmosphere during the microbial and drug production process by adjusting with the different standards certification standard required for isolators and restricted access barriers. It ensures the protection of the product, the operators and the environment at the same time.
The abundant applications of pharmaceutical isolators, vary for production and control purposes. It is used while handling, transferring or packing solid semi-solid or powder pharma drugs, handling and filing solutions and infusions. The pharmaceutical isolators are applied in sterility testing, aseptic handling of tissues or biological production systems or pathogenic samples, etc. It can be used for the production and control of drugs and pharmaceutical products. The surge in demand for the isolators across pharmaceutical and biotechnology industry, along with low operational cost, high maintenance of aseptic condition in the production of pharmaceutical products and growing demand of biopharmaceutical industry are the factors expected to drive the market growth, in the forecast period.
Also, strategic initiative by market players, technological progressions in pharmaceutical isolators, high sterility assurance and increasing investment for healthcare infrastructure. These factors increase in the demand for pharmaceutical isolators market.
Europe Pharmaceutical Isolator Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
Growing demand for the pharmaceutical isolators across booming pharmaceutical
Pharmaceutical isolator is a separative device that divides a pharmaceutical procedure or activity from the operator and the adjacent environment. It is used for various purposes such as:
- Providing a categorized aseptic environment for an activity or procedure and guarding it from microbial and non-microbial contamination rising from the operator and adjacent environment which is referred to product protection.
- Protective product from contamination produced by other product and procedure, moreover at the same time or during earlier operations. This is referred to as safeguard against method generated contamination or cross- contamination.
The Increasing contamination problems in the manufacturing unit in which comes isolator that create a demand for Pharmaceutical isolator that helps in contamination and de-contamination.
- Low operational cost of pharmaceutical isolators
Enclosures that are sealed to some standard of leak tightness that comprises inside qualified controlled environment, at modification with the surrounding conditions isolator application reaches from R&D by the production of pharmaceuticals to laboratory use, especially for the microbiological quality control. Whereas pharmaceutical aseptic production has extremely high standards of cleanness almost completely particle free and germ free environments for the aseptic production.
Due to growth in the pharma industry and the widening product range more and more manufacturers and suppliers needs to think about investments in latest added technologies of the clean room technology.
Aseptic processing of the pharmaceutical drugs is the major factor need to be included in good manufacturing practices meeting the government regulations. The high cost of the maintenance of the aseptic condition by clean room technology which is around 62% higher than the pharmaceutical isolators, shifting the manufacturers to acquire isolator’s technology and constraining the overall manufacturing cost of the pharmaceutical products.
Restraint
Stringent governmental regulations
Active Pharmaceutical Ingredients (API) and intermediates for pharmaceutical use (for instance biological, radiopharmaceutical, and pharmaceutical) and those used to production drugs for clinical trials are regulated under the Divisions 1A and 2, Part C of the Food and Drug Regulations.
- Division 1A, Part C of the Food and Drug Regulations describes activities for which Good Manufacturing Practices (GMP) compliance is required and must be demonstrated prior to the issuance of an API establishment license (EL).
- Division 2, Part C of the Food and Drug Regulations defines the requirements for the GMP of APIs and API intermediates, which are interpreted in the present guidance document.
Due to this strict regulation by the government that has to be followed for the production by the Good Manufacturing Practices (GMP) Guidelines for Active Pharmaceutical Ingredients (API) - (GUI-0104) which constraining the market growth rate.
Opportunity
- Strategic initiatives by market players
The rise in the pharmaceutical isolators market increases the need for strategic business ideas. It includes a partnership, business expansion, and other development. The rising demand for pharmaceuticals is significantly increasing the demand for excipient and to cope with this demand companies are building new manufacturing sites among other strategic initiatives.
These strategic initiatives such as product launches, agreement and business expansion by the major market player will boost the pharmaceutical isolator market growth and is expected to act as an opportunity for the Europe medical display market.
Challenge
Lack of skilled expertise
The shortage of skilled expertise would challenge the pace of recovery and growth in one place. Often, the people who are unemployed in one place have skills that are in short supply elsewhere. Moreover, rapid technological advancement in this field also leads to lack of expertise.
Lack of skilled professionals while handling the pharmaceutical isolators poses a major challenge while selecting and developing the pharmaceutical isolators. The data by the Phys.org 2003 mentions the medical display industries are facing a shortage of workers due to increase demand of pharmaceutical isolators in Asia-Pacific region and severe scarcity of micro chips used in LED and LCD display, which increases the price lead times of LCD production.
As skill demands are too high, it has manifested as a challenge to retain and manage skill-specified professionals. Moreover, technological advancement is another aspect that leads to the increased demand for skilled professionals. Neurologists report significant unmet supportive care needs and barriers in their centers with only a small minority rating themselves as competently providing supportive care. There is an urgent need for education of neurologists and professionals for treatment of dementia and procuring available supportive care resources. Lack of trained and experienced professionals and persistent skill gaps limit the employability prospects and access to quality jobs. It is therefore apparent that availability of professionals equipped with adequate skills is expected to challenge the market growth.
Post-COVID-19 Impact on Europe Pharmaceutical Isolator Market
The COVID-19 pandemic has become the world's most serious threat. It wreaked havoc in many stores and businesses around the world. The pandemic, on the other hand, has provided many opportunities for pharmaceutical and biopharmaceutical companies to expand their research and development activities to develop new vaccines against the new coronavirus. Companies are conducting clinical trials to try to stop the spread of the COVID-19 virus. Pharmaceutical insulator suppliers to biopharmaceutical organizations have more opportunities as the number of clinical trials increases.
Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities and product launch and strategic partnerships to improve the technology and test results involved in the pharmaceutical medical display market.
Recent Developments
- In June 2022, the company announced a partnership with Medical Supply Company (MSC) to market and service Jacomex equipment to the pharmaceutical and pharmaceutical industries in Ireland. MSC has many years of recognized expertise in the market with field teams closest to customers and company’s commercial team currently working abroad had the pleasure of welcoming Cian Murphy and finalizing the agreement between Jacomex and MSC. The beginning of a long and fruitful collaboration. This has helped the company to expand their business.
- In January 2022, Clario partnered with XingImaging, a radiopharmaceutical production and positron emission tomography (PET) acquisition company, to deliver PET imaging clinical trials for testing novel therapeutics in China. The partnership offers to share the joint resources and neuroscience experts of Clario and XingImaging to expedite the startup of clinical trials and drug discovery in China.
Europe Pharmaceutical isolator market Scope
유럽 제약용 아이솔레이터 시장은 유형, 압력, 응용 프로그램, 구성, 시스템 유형, 최종 사용자 및 유통 채널로 세분화됩니다. 세그먼트 간의 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.
유럽 제약 분리기 시장, 유형별
- 무균 격리기
- 격리 격리 장치
- 바이오 아이솔레이터
- 샘플링 및 무게 측정 분리기
- 활성 약리 성분(API) 제조 분리제
- 방사성의약품 격리기
- 생산 분리기
- 기타
유럽 제약용 분리기 시장은 유형을 기준으로 무균 분리기, 격리 분리기, 생물학적 분리기, 샘플링 및 계량 분리기, 활성 제약 성분(API) 제조 분리기, 방사성 의약품 분리기, 생산 분리기 및 기타로 구분됩니다.
시스템 유형별 유럽 제약 분리기 시장
- 폐쇄 시스템
- 오픈 시스템
유럽 약제학적 분리기 시장은 시스템 유형을 기준으로 폐쇄형 시스템과 개방형 시스템으로 구분됩니다.
유럽 제약용 분리기 시장, 압력별
- 긍정적인 압력
- 부정적인 압력
유럽 제약용 분리기 시장은 압력을 기준으로 양압과 음압으로 구분됩니다.
유럽 제약 분리기 시장, 구성별
- 플로어 스탠딩
- 모듈식
- 이동하는
- 콤팩트
- 테이블탑
- 가지고 다닐 수 있는
- 기타
유럽 약제용 분리기 시장은 구성을 기준으로 바닥형, 모듈형, 이동식, 콤팩트형, 테이블탑형, 휴대형, 기타로 구분됩니다.
유럽 제약용 분리기 시장, 응용 분야별
- 무균 테스트
- 조작
- 샘플링/ 무게 측정/ 분포
- 의료기기 제조
- 기타
유럽 제약용 분리기 시장은 응용 분야를 기준으로 무균 테스트, 제조, 샘플링/계량/유통, 의료 기기 제조 등으로 구분됩니다.
최종 사용자별 유럽 제약 분리기 시장
- 병원
- 진단 실험실
- 학술 및 연구 기관
- 제약 및 생명공학 회사
- 계약 연구 기관
- 기타
유럽 제약용 분리기 시장은 최종 사용자를 기준으로 병원, 진단 실험실, 학술 및 연구 기관, 제약 및 생명 공학 회사, 계약 연구 기관 및 기타로 구분됩니다.
유럽 제약 분리기 시장, 유통 채널별
- 직접 입찰
- 소매 판매
- 제3자 유통업체
유럽 제약용 분리기 시장은 유통 채널을 기준으로 직접 입찰, 소매 판매, 제3자 유통업체로 구분됩니다.
유럽 제약용 분리기 시장 지역 분석/통찰력
유럽 제약용 분리기 시장을 분석하고, 유형, 압력, 응용 분야, 구성, 시스템 유형, 최종 사용자 및 유통 채널에 대한 시장 규모 정보를 제공합니다.
이 시장 보고서에 포함된 국가로는 독일, 프랑스, 영국, 이탈리아, 스페인, 러시아, 터키, 벨기에, 네덜란드, 스위스, 그리고 나머지 유럽 국가가 있습니다.
2022년에는 독일이 제약 시장의 급속한 성장과 제약 장비 생산의 증가, 신흥 시장의 수요 증가, 의료 산업의 확장으로 주도권을 잡을 것으로 예상됩니다.
보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 유럽 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
경쟁 환경 및 유럽 제약용 분리기 시장 점유율 분석
유럽 제약 아이솔레이터 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, R&D 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭 및 호흡, 응용 프로그램 우세, 기술 수명선 곡선이 있습니다. 위에 제공된 데이터 포인트는 유럽 제약 아이솔레이터 시장에 대한 회사의 초점과만 관련이 있습니다.
유럽 제약용 분리기 시장에서 활동하는 주요 기업으로는 Getinge, SKAN AG, Hosokawa micron ltd, Gelman Singapore, Azbil Corporation, Germfree Laboratories, Inc., M. Braun Inertgas-Systeme Gmbh, Nuaire, Iteco SRL, Comecer SPA, Hecht Technologie Gmbh, Steriline SRL, Envair Limited, Tema Sinergie SPA, Schematic Engineering Industries, Chiyoda Corporation, Chamunda Pharma Machinery Pvt. Ltd, Bioquell (Ecolab Solution), Jacomex, Fedegari Autoclavi SpA, LAF Technologies, ISO Tech Design, Cytiva, Esco Pharma 등이 있습니다.
연구 방법론: 유럽 제약 아이솔레이터 시장
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 유럽 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가 전화를 요청하십시오.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE PHARMACEUTICAL ISOLATOR MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 SOURCE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 INDUSTRIAL INSIGHTS:
5 EUROPE PHARMACEUTICAL ISOLATORS MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING DEMAND FOR THE PHARMACEUTICAL ISOLATORS ACROSS BOOMING PHARMACEUTICAL
6.1.2 LOW OPERATIONAL COST OF PHARMACEUTICAL ISOLATORS
6.1.3 HIGH MAINTENANCE OF ASEPTIC CONDITIONS IN THE PRODUCTION OF PHARMACEUTICAL PRODUCTS
6.1.4 LOW OPERATING COST OF PHARMACEUTICAL ISOLATORS & GROWING DEMAND IN THE BIOPHARMACEUTICAL INDUSTRY
6.2 RESTRAINTS
6.2.1 STRINGENT GOVERNMENTAL REGULATIONS
6.2.2 HIGH COST OF INSTALLATION & LIMITED ADOPTION OF RABS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
6.3.2 TECHNOLOGICAL ADVANCEMENTS IN PHARMACEUTICAL ISOLATORS
6.3.3 HIGH STERILITY ASSURANCE
6.4 CHALLENGES
6.4.1 LACK OF SKILLED EXPERTISE
6.4.2 ENGINEERING CHALLENGES FACED WHILE DESIGNING THE PHARMACEUTICAL ISOLATORS
7 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY TYPE
7.1 OVERVIEW
7.2 ASEPTIC ISOLATOR
7.3 ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURING ISOLATORS
7.4 CONTAINMENT ISOLATORS
7.5 BIO ISOLATORS
7.6 SAMPLING AND WEIGHING ISOLATORS
7.7 RADIOPHARMACEUTICAL ISOLATORS
7.8 PRODUCTION ISOLATORS
7.9 OTHERS
8 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE
8.1 OVERVIEW
8.2 OPEN SYSTEM
8.3 CLOSED SYSTEM
9 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE
9.1 OVERVIEW
9.2 POSITIVE PRESSURE
9.3 NEGATIVE PRESSURE
10 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION
10.1 OVERVIEW
10.2 FLOOR STANDING
10.3 MODULAR
10.4 MOBILE
10.5 COMPACT
10.6 TABLE TOP
10.7 PORTABLE
10.8 OTHERS
11 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 STERILITY TESTING
11.3 MANUFACTURING
11.4 SAMPLING/WEIGHING/DISTRIBUTION
11.5 MEDICAL DEVICE MANUFACTURING
12 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
12.4 THIRD PARTY DISTRIBUTORS
13 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY END USER
13.1 OVERVIEW
13.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
13.2.1 STERILE FILTERING
13.2.2 AMPULE FILLING
13.2.3 SYRINGE FILLING
13.2.4 SAMPLING
13.2.5 SAMPLE TESTING
13.2.6 STERILITY TESTING
13.2.7 PACKAGING
13.2.8 OTHERS
13.3 CONTRACT RESEARCH ORGANIZATION
13.3.1 STERILE FILTERING
13.3.2 AMPULE FILLING
13.3.3 SYRINGE FILLING
13.3.4 SAMPLING
13.3.5 SAMPLE TESTING
13.3.6 STERILITY TESTING
13.3.7 PACKAGING
13.3.8 OTHERS
13.4 ACADEMIC AND RESEARCH INSTITUTES
13.4.1 STERILE FILTERING
13.4.2 AMPULE FILLING
13.4.3 SYRINGE FILLING
13.4.4 SAMPLING
13.4.5 SAMPLE TESTING
13.4.6 STERILITY TESTING
13.4.7 PACKAGING
13.4.8 OTHERS
13.5 HOSPITALS
13.5.1 STERILE FILTERING
13.5.2 AMPULE FILLING
13.5.3 SYRINGE FILLING
13.5.4 SAMPLING
13.5.5 SAMPLE TESTING
13.5.6 STERILITY TESTING
13.5.7 PACKAGING
13.5.8 OTHERS
13.6 DIAGNOSTIC LABORATORIES
13.6.1 STERILE FILTERING
13.6.2 AMPULE FILLING
13.6.3 SYRINGE FILLING
13.6.4 SAMPLING
13.6.5 SAMPLE TESTING
13.6.6 STERILITY TESTING
13.6.7 PACKAGING
13.6.8 OTHERS
13.7 OTHERS
14 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY REGION
14.1 EUROPE
14.1.1 GERMANY
14.1.2 FRANCE
14.1.3 U.K.
14.1.4 ITALY
14.1.5 RUSSIA
14.1.6 SPAIN
14.1.7 TURKEY
14.1.8 NETHERLANDS
14.1.9 SWITZERLAND
14.1.10 BELGIUM
14.1.11 REST OF EUROPE
15 EUROPE PHARMACEUTICAL ISOLATORS MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: EUROPE
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 GETINGE AB
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 CYTIVA (A SUBSIDIARY OF DANAHER CORPORATION)
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 AZBIL CORPORATION
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 CHIYODA CORPORATION
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 HOSOKAWA MICRON LTD
17.5.1 COMPANY SNAPSHOT
17.5.2 COMPANY SHARE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENTS
17.6 BIOQUELL, AN ECOLAB SOLUTION (A SUBSIDIARY OF ECOLAB)
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 CHAMUNDA PHARMA MACHNIERY
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENTS
17.8 COMECER S.P.A. (A SUBSIDIARY OF ATS AUTOMATION TOOLS) (2021)
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 ENVAIR TECHNOLOGY
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENTS
17.1 ESCO MICRO PTE. LTD
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 FEDEGARI AUTOCLAVI S.P.A
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENTS
17.12 GERMFREE LABORATORIES, INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.13 GELMAN SINGAPORE
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENTS
17.14 HECT TECHNOLOGIE GMBH (2021)
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.15 ISO TECH DESIGN
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENTS
17.16 ITECO SRL
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENT
17.17 JACOMEX
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 LAF TECHNOLOGIES
17.18.1 COMPANY SNAPSHOT
17.18.2 PRODUCT PORTFOLIO
17.18.3 RECENT DEVELOPMENTS
17.19 MBRAUN.(2021)
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENT
17.2 NUAIRE (A SUBSIDIARY OF GENUIT GROUP PLC)
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENTS
17.21 STERILINE (2021)
17.21.1 COMPANY SNAPSHOT
17.21.2 PRODUCT PORTFOLIO
17.21.3 RECENT DEVELOPMENTS
17.22 SCHEMATIC ENGINEERING INDUSTRY
17.22.1 COMPANY SNAPSHOT
17.22.2 PRODUCT PORTFOLIO
17.22.3 RECENT DEVELOPMENTS
17.23 SKAN AG
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENT
17.24 TEMA SINERGIE S.P.A
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
표 목록
TABLE 1 OPERATING COSTS FOR ASEPTIC PRODUCTION UNDER RABS OR ISOLATOR
TABLE 2 APPLICATION OF GUI-0104 TO API MANUFACTURING
TABLE 3 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 4 EUROPE ASEPTIC ISOLATOR IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 EUROPE ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURING ISOLATORS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 EUROPE CONTAINMENT ISOLATORS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 EUROPE BIO ISOLATORS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE SAMPLING AND WEIGHING ISOLATORS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 EUROPE RADIOPHARMACEUTICAL ISOLATORS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE PRODUCTION ISOLATORS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE OTHERS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 13 EUROPE OPEN SYSTEM IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE CLOSED SYSTEM IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 16 EUROPE POSITIVE PRESSURE IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE NEGATIVE PRESSURE IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE FLOOR STANDING IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE MODULAR IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 EUROPE MOBILE IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 EUROPE COMPACT IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 EUROPE TABLE TOP IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE PORTABLE IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 EUROPE OTHERS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 27 EUROPE STERILITY TESTING IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 EUROPE MANUFACTURING IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 EUROPE SAMPLING/WEIGHING/DISTRIBUTION IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 EUROPE MEDICAL DEVICE MANUFACTURING IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 32 EUROPE DIRECT TENDER IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 EUROPE RETAIL SALES INPHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 EUROPE THIRD PARTY DISTRIBUTORS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 36 EUROPE PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 EUROPE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 38 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 40 EUROPE ACADEMIC AND RESEARCH INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 EUROPE ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 42 EUROPE HOSPITALS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 43 EUROPE HOSPITALS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 44 EUROPE DIAGNOSTIC LABARATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 45 EUROPE DIAGNOSTICS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 46 EUROPE OTHERS IN PHARMACEUTICAL ISOLATOR MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 47 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 48 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 50 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 51 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 52 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 53 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 54 EUROPE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 55 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 56 EUROPE ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 57 EUROPE HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 58 EUROPE DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 59 EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 60 GERMANY PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 GERMANY PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 62 GERMANY PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 63 GERMANY PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 64 GERMANY PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 65 GERMANY PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 66 GERMANY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 67 GERMANY CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 68 GERMANY ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 69 GERMANY HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 70 GERMANY DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 71 GERMANY PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 72 FRANCE PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 73 FRANCE PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 74 FRANCE PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 75 FRANCE PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 76 FRANCE PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 77 FRANCE PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 78 FRANCE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 79 FRANCE CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 80 FRANCE ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 81 FRANCE HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 82 FRANCE DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 83 FRANCE PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 84 U.K. PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 85 U.K. PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 86 U.K. PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 87 U.K. PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 88 U.K. PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 89 U.K. PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 90 U.K. PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 91 U.K. CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 92 U.K. ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 93 U.K. HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 94 U.K. DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 95 U.K. PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 96 ITALY PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 ITALY PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 98 ITALY PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 99 ITALY PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 100 ITALY PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 101 ITALY PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 102 ITALY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 103 ITALY CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 104 ITALY ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 105 ITALY HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 106 ITALY DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 107 ITALY PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 108 RUSSIA PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 RUSSIA PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 110 RUSSIA PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 111 RUSSIA PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 112 RUSSIA PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 113 RUSSIA PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 114 RUSSIA PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 115 RUSSIA CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 116 RUSSIA ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 117 RUSSIA HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 118 RUSSIA DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 119 RUSSIA PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 120 SPAIN PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 121 SPAIN PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 122 SPAIN PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 123 SPAIN PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 124 SPAIN PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 125 SPAIN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 126 SPAIN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 127 SPAIN CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 128 SPAIN ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 129 SPAIN HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 130 SPAIN DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 131 SPAIN PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 132 TURKEY PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 133 TURKEY PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 134 TURKEY PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 135 TURKEY PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 136 TURKEY PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 137 TURKEY PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 138 TURKEY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 139 TURKEY CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 140 TURKEY ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 141 TURKEY HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 142 TURKEY DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 143 TURKEY PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 144 NETHERLAND PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 145 NETHERLAND PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 146 NETHERLAND PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 147 NETHERLAND PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 148 NETHERLAND PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 149 NETHERLAND PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 150 NETHERLAND PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 151 NETHERLAND CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 152 NETHERLAND ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 153 NETHERLAND HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 154 NETHERLAND DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 155 NETHERLAND PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 156 SWITZERLAND PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 157 SWITZERLAND PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 158 SWITZERLAND PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 159 SWITZERLAND PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 160 SWITZERLAND PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 161 SWITZERLAND PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 162 SWITZERLAND PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 163 SWITZERLAND CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 164 SWITZERLAND ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 165 SWITZERLAND HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 166 SWITZERLAND DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 167 SWITZERLAND PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 168 BELGIUM PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 169 BELGIUM PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE, 2020-2029 (USD MILLION)
TABLE 170 BELGIUM PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE, 2020-2029 (USD MILLION)
TABLE 171 BELGIUM PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION, 2020-2029 (USD MILLION)
TABLE 172 BELGIUM PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 173 BELGIUM PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 174 BELGIUM PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 175 BELGIUM CONTRACT RESEARCH ORGANIZATIONS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 176 BELGIUM ACADEMIC RESEARCH & INSTITUTES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 177 BELGIUM HOSPITALS LABORATORIES IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 178 BELGIUM DIAGNOSTICS IN PHARMACEUTICAL ISOLATOR MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 179 BELGIUM PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 180 REST OF EUROPE PHARMACEUTICAL ISOLATOR MARKET, BY TYPE, 2020-2029 (USD MILLION)
그림 목록
FIGURE 1 EUROPE PHARMACEUTICAL ISOLATOR MARKET: SEGMENTATION
FIGURE 2 EUROPE PHARMACEUTICAL ISOLATOR MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE PHARMACEUTICAL ISOLATOR MARKET: DROC ANALYSIS
FIGURE 4 EUROPE PHARMACEUTICAL ISOLATOR MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 EUROPE PHARMACEUTICAL ISOLATOR MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE PHARMACEUTICAL ISOLATOR MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE PHARMACEUTICAL ISOLATOR MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 EUROPE PHARMACEUTICAL ISOLATOR MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE PHARMACEUTICAL ISOLATOR MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE PHARMACEUTICAL ISOLATOR MARKET: SEGMENTATION
FIGURE 11 INCREASING USE OF PHARMACEUTICAL ISOLATORS IS EXPECTED TO DRIVE THE EUROPE PHARMACEUTICAL ISOLATOR MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 ASEPTIC ISOLATORS IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE PHARMACEUTICAL ISOLATOR MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE PHARMACEUTICAL ISOLATOR MARKET
FIGURE 14 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY TYPE, 2021
FIGURE 15 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 16 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 17 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY SYSTEM TYPE, 2021
FIGURE 19 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY SYSTEM TYPE, 2022-2029 (USD MILLION)
FIGURE 20 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY SYSTEM TYPE, CAGR (2022-2029)
FIGURE 21 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY SYSTEM TYPE, LIFELINE CURVE
FIGURE 22 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY PRESSURE, 2021
FIGURE 23 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY PRESSURE, 2022-2029 (USD MILLION)
FIGURE 24 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY PRESSURE, CAGR (2022-2029)
FIGURE 25 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY PRESSURE, LIFELINE CURVE
FIGURE 26 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY CONFIGURATION, 2021
FIGURE 27 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY CONFIGURATION, 2022-2029 (USD MILLION)
FIGURE 28 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY CONFIGURATION, CAGR (2022-2029)
FIGURE 29 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY CONFIGURATION, LIFELINE CURVE
FIGURE 30 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY APPLICATION, 2021
FIGURE 31 EUROPEPHARMACEUTICAL ISOLATOR MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 32 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 33 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 34 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 35 EUROPEPHARMACEUTICAL ISOLATOR MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 36 EUROPEPHARMACEUTICAL ISOLATOR MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 37 EUROPEPHARMACEUTICAL ISOLATOR MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 EUROPE PHARMACEUTICAL ISOLATOR MARKET : BY END USER, 2021
FIGURE 39 EUROPE PHARMACEUTICAL ISOLATOR MARKET : BY END USER, 2022-2029 (USD MILLION)
FIGURE 40 EUROPE PHARMACEUTICAL ISOLATOR MARKET : BY END USER, CAGR (2022-2029)
FIGURE 41 EUROPE PHARMACEUTICAL ISOLATOR MARKET : BY END USER, LIFELINE CURVE
FIGURE 42 EUROPE PHARMACEUTICAL ISOLATOR MARKET: SNAPSHOT (2021)
FIGURE 43 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY COUNTRY (2021)
FIGURE 44 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY COUNTRY (2022 & 2029)
FIGURE 45 EUROPE PHARMACEUTICAL ISOLATOR MARKET: BY COUNTRY (2021 & 2029)
FIGURE 46 EUROPE PHARMACEUTICAL ISOLATOR MARKET: TYPE (2022-2029)
FIGURE 47 EUROPE PHARMACEUTICAL ISOLATORS MARKET: COMPANY SHARE 2021 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
